2342 — TransGenic Cashflow Statement
0.000.00%
Last trade - 00:00- ¥3bn
- ¥3bn
- ¥13bn
- 27
- 65
- 10
- 22
Annual cashflow statement for TransGenic, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 695 | 2,768 | -332 | 43.1 | -676 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 158 | -680 | 166 | 78.9 | 262 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 264 | -526 | -1,448 | -665 | 266 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | 1,369 | 1,789 | -1,430 | -392 | 94.1 |
| Capital Expenditures | -146 | -532 | -306 | -266 | -175 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 194 | 1,514 | 90.3 | -15.3 | -112 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 48.4 | 982 | -216 | -281 | -288 |
| Financing Cash Flow Items | -146 | -73.9 | -16.1 | -16.1 | -22.9 |
| Other Financing Cash Flow | |||||
| Total Cash Dividends Paid | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 10 | -1,183 | 485 | -343 | 265 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1,427 | 1,588 | -1,159 | -993 | 75.6 |